Compare AXG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AXG | ANL |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.4M | 731.6M |
| IPO Year | N/A | 2022 |
| Metric | AXG | ANL |
|---|---|---|
| Price | $3.55 | $11.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 115.3K | ★ 306.1K |
| Earning Date | 01-09-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.53 | $36.02 |
| Revenue Next Year | $54.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $0.88 |
| 52 Week High | $4.75 | $17.25 |
| Indicator | AXG | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 45.14 |
| Support Level | $3.49 | $6.92 |
| Resistance Level | $3.94 | $12.09 |
| Average True Range (ATR) | 0.11 | 1.34 |
| MACD | -0.02 | -0.44 |
| Stochastic Oscillator | 10.34 | 27.73 |
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.